SpringWorks Therapeutics Inc

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company whose drug development pipeline relies on animal testing as a required component of the preclinical research and regulatory approval process. The company’s lead investigational compounds, including nirogacestat for desmoid tumors, would have undergone standard in vivo testing in animal models to assess safety, pharmacokinetics, and efficacy prior to human clinical trials.

Cruelty Free Investors, a screening resource for ethical investors, lists SpringWorks Therapeutics among “Companies That Exploit Animals” specifically for animal testing. This classification reflects the standard, industry-wide practice in biopharmaceutical development where animal models are used to satisfy regulatory requirements from agencies like the U.S. Food and Drug Administration. The company has not publicly announced a commitment to adopt or fund alternative non-animal testing methodologies as a core part of its research strategy.